Sevasemten

Phase 2Small molecule

EEdgewise Therapeutics, Inc.

Sevasemten is one of 44 small molecule programs targeting Becker muscular dystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Becker Muscular DystrophyActive, not recruiting

Duchenne Muscular DystrophyActive, not recruiting

Becker Muscular DystrophyPhase 2

Active, not recruiting

Duchenne Muscular DystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

125 competitors in Duchenne Muscular Dystrophy

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Phase 3

2 2

Aldactone

Pfizer

Phase 3

1 3

Rifadin

Sanofi

Phase 3

1 4

Nolvadex

AstraZeneca

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

6 6

Rayos

RRoxane Laboratories

Phase 3

5 7

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 8

Duvyzat

Italfarmaco

Phase 3

2 9

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 10

ENSPRYNG

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Becker Muscular Dystrophy

NCT05291091

Q1 2027

Phase 2Active, not recruiting

Duchenne Muscular Dystrophy

NCT05540860

Phase 2Active, not recruiting

Duchenne Muscular Dystrophy

NCT06100887

Clinical

Trials by Indication[1]

Becker muscular dystrophy3 trials

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Active, not recruiting·EEdgewise Therapeutics, Inc.·Phase 2·NCT05291091·244 enrolled

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

Completed·EEdgewise Therapeutics, Inc.·Phase 1·NCT05160415·12 enrolled

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Enrolling by invitation·EEdgewise Therapeutics, Inc.·Phase 2·NCT06066580·260 enrolled

Duchenne Muscular Dystrophy2 trials

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

Active, not recruiting·EEdgewise Therapeutics, Inc.·Phase 2·NCT06100887·43 enrolled

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Active, not recruiting·EEdgewise Therapeutics, Inc.·Phase 2·NCT05540860·76 enrolled

Unspecified1 trial

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

Completed·EEdgewise Therapeutics, Inc.·Phase 1·NCT06916897·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Sevasemten. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sevasemten compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sevasemten. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Edgewise Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEdgewise Therapeutics, Inc.

Sevasemten

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Trials by Indication[1]

Becker muscular dystrophy3 trials

Duchenne Muscular Dystrophy2 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News